Cargando…

Evaluation of Omalizumab From a Health Plan Perspective

OBJECTIVES: To review the pathophysiology of allergic asthma and information on the pharmacology, clinical efficacy, safety profile, and direct drug costs for omalizumab to provide a basis for a defined role of this agent in allergic asthma therapy in managed care organizations. SUMMARY: Omalizumab...

Descripción completa

Detalles Bibliográficos
Autores principales:	Belliveau, Paul P., Lahoz, Monina R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2005
Materias:	Formulary Management
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10438166/ https://www.ncbi.nlm.nih.gov/pubmed/16300417 http://dx.doi.org/10.18553/jmcp.2005.11.9.735

Ejemplares similares

Health Plan Budget Impact Analysis for Pimecrolimus
por: Chang, Jane, et al.
Publicado: (2005)

Evaluation of Erlotinib in Advanced Non-Small Cell Lung Cancer: Impact on the Budget of a U.S. Health Insurance Plan
por: Ramsey, Scott D., et al.
Publicado: (2006)

AMCP Format Dossier Requests: Manufacturer Response and Formulary Implications for One Large Health Plan
por: Spooner, Joshua J., et al.
Publicado: (2007)

Pharmaceutical Technology Assessment: Perspectives from Payers
por: Leung, Musetta Y., et al.
Publicado: (2012)

Administrative Claims Analysis of Utilization and Costs of Care in Health Plan Members With Atopic Dermatitis Who Had Prior Use of a Topical Corticosteroid and Who Initiate Therapy With Pimecrolimus or Tacrolimus
por: Delea, Thomas E., et al.
Publicado: (2007)

Multicenter Drug Use Evaluation of Tamsulosin and Availability of Guidance Criteria for Nonformulary Use in the Veterans Affairs Health System
por: Burk, Muriel, et al.
Publicado: (2004)

Managed Care Perspective on Three New Agents for Type 2 Diabetes
por: VanDeKoppel, Shawna, et al.
Publicado: (2008)

Pharmacy Benefit Forecast for a New Interferon Beta-1a for the Treatment of Multiple Sclerosis: Development of a First-Line Decision Tool for Pharmacy-Budget Planning Using Administrative Claims Data
por: Meryer, Christina
Publicado: (2003)

Evaluation of Clostridium difficile-Associated Diarrhea With a Drug Formulary Change in Preferred Fluoroquinolones
por: Walbrown, Molly A., et al.
Publicado: (2008)

Clinical and Economic Outcomes of Conversion of Simvastatin to Lovastatin in a Group-Model Health Maintenance Organization
por: Billups, Sarah J., et al.
Publicado: (2005)

Examining the Value and Quality of Health Economic Analyses: Implications of Utilizing the QHES
por: Ofman, Joshua J., et al.
Publicado: (2003)

Evaluation of the Cost-Effectiveness of Entecavir Versus Lamivudine in Hepatitis BeAg-Positive Chronic Hepatitis B Patients
por: Yuan, Yong, et al.
Publicado: (2008)

A Population Approach to Disease Management: Hepatitis C Direct-Acting Antiviral Use in a Large Health Care System
por: Belperio, Pamela S., et al.
Publicado: (2014)

A Comparison of the Cost-Effectiveness of Almotriptan and Sumatriptan in the Treatment of Acute Migraine Using a Composite Efficacy/Tolerability End Point
por: Williams, Paul, et al.
Publicado: (2004)

Comparison of Risedronate to Alendronate and Calcitonin for Early Reduction of Nonvertebral Fracture Risk: Results From a Managed Care Administrative Claims Database
por: Watts, Nelson B., et al.
Publicado: (2004)

A Comparison of Clinical Practice Guidelines in the Initial Pharmacological Management of New-Onset Epilepsy in Adults
por: Payakachat, Nalin, et al.
Publicado: (2006)

Do Decision-Analytic Models Identify Cost-Effective Treatments? A Retrospective Look at Helicobacter Pylori Eradication
por: Fairman, Kathleen A., et al.
Publicado: (2003)

Formulary Review of 2 New Biologic Agents: Tocilizumab for Rheumatoid Arthritis and Ustekinumab for Plaque Psoriasis
por: Schafer, Jeremy A., et al.
Publicado: (2010)

Cost-Effectiveness Analysis of Simvastatin and Lovastatin/Extended-Release Niacin to Achieve LDL and HDL Goal Using NHANES Data
por: Armstrong, Edward P., et al.
Publicado: (2004)

Industry's Perception of Presenting Pharmacoeconomic Models to Managed Care Organizations
por: Olson, Bridget M., et al.
Publicado: (2003)

Cost Implications of Formulary Decisions on Oral Anticoagulants in Nonvalvular Atrial Fibrillation
por: Biskupiak, Joseph, et al.
Publicado: (2013)

Drug and Medical Cost Effects of a Drug Formulary Change With Therapeutic Interchange for Statin Drugs in a Multistate Managed Medicaid Organization
por: Meissner, Brian, et al.
Publicado: (2006)

Triptans for Migraine Therapy: A Comparison Based on Number Needed to Treat and Doses Needed to Treat
por: Mullins, C. Daniel
Publicado: (2005)

Similar Medication Compliance and Control of Dyslipidemia WithSimvastatin or Atorvastatin in a Staff-Model HMO Medical Clinic
por: Valdez, Connie A., et al.
Publicado: (2005)

Application of Economic Analyses in U.S. Managed Care Formulary Decisions: A Private Payer's Experience
por: Watkins, John B., et al.
Publicado: (2006)

Assessment of Clinical, Service, and Cost Outcomes of a Conversion Program of Sumatriptan to Rizatriptan ODT in Primary Care Patients With Migraine Headaches
por: Gershovich, Olga E., et al.
Publicado: (2006)

Cost-effectiveness of Four Immunomodulatory Therapies for Relapsing-Remitting Multiple Sclerosis: A Markov Model Based on Long-term Clinical Data
por: Bell, Christopher, et al.
Publicado: (2007)

Cost-Efficacy Analysis of Peginterferon alfa-2b plus Ribavirin Compared With Peginterferon alfa-2a plus Ribavirin for the Treatment of Chronic Hepatitis C
por: Malone, Daniel C., et al.
Publicado: (2005)

Clinical Monograph for Drug Formulary Review: Systemic Agents for Psoriasis/Psoriatic Arthritis
por: Fisher, Vicki S.
Publicado: (2005)

Clinical Monograph for Drug Formulary Review: Erectile Dysfunction Agents
por: Campbell, Helen Eloise
Publicado: (2005)

Product-Line Extensions and Pricing Strategies of Brand-Name Drugs Facing Patent Expiration
por: Hong, Song Hee, et al.
Publicado: (2005)

Cost-EffectivenessAnalysis of Ondansetron and Prochlorperazine for the Prevention of Postoperative Nausea andVomiting
por: Chang, Peter
Publicado: (2005)

Formulary Review of Therapeutic Alternatives for Atopic Dermatitis: Focus on Pimecrolimus
por: Weinberg, Jeffery M.
Publicado: (2005)

Effect of Patient Notification of Formulary Change on Formulary Adherence
por: Delate, Thomas, et al.
Publicado: (2005)

Cost-Effectiveness Analysis and the Formulary Decision-Making Process
por: Wang, Zhixiao, et al.
Publicado: (2004)

The U.S. Food and Drug Administration: Drug Information Resource for Formulary Recommendations
por: Marchand, Heidi C., et al.
Publicado: (2012)

Critical Review of Prasugrel for Formulary Decision Makers
por: Schafer, Jeremy
Publicado: (2009)

Proton-Pump Inhibitor Utilization Associated With the Change to Nonpreferred Formulary Status for Esomeprazole in the TRICARE Formulary
por: Linton, Andrea, et al.
Publicado: (2009)

Cost-Effectiveness of Tamsulosin, Doxazosin, and Terazosin in the Treatment of Benign Prostatic Hyperplasia
por: Ohsfeldt, Robert L., et al.
Publicado: (2004)

Formulary Management of the Protease Inhibitors Boceprevir and Telaprevir for Chronic Hepatitis C Virus
por: Tungol, Alexandra, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_b6vqrs92pq5mi8osc03hiscb1g